|
Psychiatric aspects of phosphodiesterases: An overview
Vasantmeghna S Murthy, Ajish G Mangot
Department of Psychiatry, Krishna Institute of Medical Sciences Deemed University, Karad, Satara, Maharashtra, India
Correspondence Address:
Dr. Ajish G Mangot
Department of Psychiatry, Krishna Institute of Medical Sciences Deemed University, Karad, Satara, Maharashtra
India
Phosphodiesterases (PDE) are exciting new targets in medical sciences. These enzymes are some of the key mediators of cellular functions in the body and hence are attractive sites for drug-induced modulations. With the finding that Tofisopam, a new anxiolytic, inhibits PDEs, the authors were inspired to look into the role of PDE and drugs acting on them in psychiatry. Hence, the review was undertaken. We found several research materials available highlighting the role of PDE in cellular functions and the possible newer etiological mechanisms of neuropsychiatric illnesses such as schizophrenia, depression/anxiety disorders, and cognitive dysfunction involving PDEs. We also found that there are many molecules acting on PDEs, which have the potential to alter the way we treat mental illnesses today. This article is intended to provide an in-depth look at these enzymes so that more cost-effective therapeutic molecules may be synthesized and marketed in India for managing mental illnesses.
How to cite this article:
Murthy VS, Mangot AG. Psychiatric aspects of phosphodiesterases: An overview.Indian J Pharmacol 2015;47:594-599
|
How to cite this URL:
Murthy VS, Mangot AG. Psychiatric aspects of phosphodiesterases: An overview. Indian J Pharmacol [serial online] 2015 [cited 2023 Mar 25 ];47:594-599
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2015;volume=47;issue=6;spage=594;epage=599;aulast=Murthy;type=0 |
|
